Estrogen and Your Uterine Lining: What Actually Keeps It Safe
Menopause · Hormone Science Series, Part 3
Estrogen and Your Uterine Lining: What Actually Keeps It Safe
Why women with a uterus need lining protection on estrogen, why no bleeding proves nothing, and what makes protection work. A Dallas NP explains.
A patient told me last month, "I don't bleed, so I figured everything down there is fine." She had been taking estrogen on its own for over a year. She still had her uterus.
She wasn't careless. She was told something incomplete. And that gap is what this post is about.
Estrogen tells the lining to grow
The inside lining of your uterus, the endometrium, responds to estrogen by growing. A second hormone, progesterone, is what balances that signal.
After menopause, if you take estrogen and nothing balances it, the lining keeps getting the grow signal with no stop signal. Over time it can overgrow. That overgrowth is called endometrial hyperplasia, and some forms of it can progress to endometrial cancer.
How fast it happens
Faster than many women expect. Overgrowth is not a problem that waits for decades. About 30% of women develop hyperplasia after just one year of estrogen alone, whether it is taken as a pill or through the skin. In the PEPI trial, a major study from the 1990s, women on estrogen alone for three years had far higher rates of hyperplasia than women on placebo, including the more concerning atypical type. The cases appeared evenly across all three years, so there was no safe early stretch.
Every group in that trial that took estrogen together with a progestogen looked like the placebo group.
Lining overgrowth after more than 1 year of estrogen alone
Time matters more than strength for cancer
For overgrowth, the strength of estrogen matters. A 2025 Cochrane review found that moderate and higher strengths sharply raised hyperplasia, while the lowest strengths showed no clear increase.
For cancer, time is the bigger driver. Risk roughly doubles with under five years of estrogen alone and climbs to around seven times higher beyond five years. And it does not reset when you stop. Risk stays elevated for years afterward. FDA labeling says it can persist at least 8 to 15 years after stopping.
Why "no bleeding" proves nothing
Here is the part I most want you to remember. Bleeding is a poor alarm.
Many women taking estrogen alone bleed. In one set of trials, about two out of three women on estrogen alone had at least one bleeding episode, compared with about one in ten on placebo, and nearly half ended up having a biopsy. Women with obesity were even more likely to bleed.
And the high hyperplasia rates in those studies were found on biopsies done on a schedule, not because women had symptoms. So the research tells us a woman without bleeding has not been shown to be safe. We do not know exactly how often hyperplasia causes no bleeding at all. But the absence of bleeding cannot clear your lining.
That cuts the other way too. If you bleed after menopause, it always gets checked. Bleeding on estrogen is common and often harmless, and it still earns a look, because the only way to know what the lining is doing is to evaluate it.
The protection has to be adequate
The answer for women with a uterus who use estrogen pills, patches or gels is a progestogen. That might be micronized progesterone, another progestogen, or a hormonal IUD. But simply having one on your list is not enough. It has to be adequate.
Enough days. In research, a progestogen taken fewer than 10 days a month raised cancer risk. Taken longer each cycle, it was neutral. Taken every day, it was protective.
The right form. Progesterone cream on the skin does not protect the lining. Long, stretched-out cycles used over many years raised risk too. Daily combined regimens and the hormonal IUD lowered it.
Actually taken. A large French study found higher risk after five years of estrogen with micronized progesterone. Biopsy studies of micronized progesterone are reassuring, and missed doses may explain that finding. Either way, skipped doses count. If you have trouble remembering, tell me. We can talk about a schedule or a form that fits your life better, because the protection only exists on the days you take it.
A 2026 Veterans Affairs and Department of Defense guideline found no strong evidence that one progestogen beats another for protecting the lining.
The exception: low-dose vaginal estrogen
Low-dose vaginal estrogen, used for dryness, irritation or bladder symptoms, is different. Across 20 clinical trials, endometrial cancer and hyperplasia were very rare, and guidelines do not recommend adding a progestogen or routine lining checks for it alone. Any bleeding after menopause still gets evaluated.
Weight and your own hormones
Excess body weight, irregular ovulation and PCOS can expose the lining to your own unbalanced estrogen, through the same mechanism. Remember how insulin resistance changes hormone-carrying proteins? It shows up here too. Studies disagree on whether weight makes estrogen therapy riskier or less risky for the lining, and that question is still open.
Questions women ask us
I don't bleed at all. Do I still need protection?
Yes, if you have a uterus and use systemic estrogen. No bleeding does not prove your lining is safe.
Can I use progesterone cream instead?
Research found progesterone through the skin does not protect the lining. Ask about forms that do.
Does my risk go away if I stop estrogen?
Not right away. After estrogen alone, risk stays elevated for years after stopping, which is one more reason to protect the lining from the start.
Do I need a progestogen with vaginal estrogen?
Not for low-dose vaginal estrogen used alone. Any bleeding after menopause still needs a check.
Labs first, a real review, and a plan built around your history. Care is available in person in Dallas or remotely.
Book a Start VisitThis article is general education, not medical advice for any individual. Talk with your own clinician about what fits your history.
Written and clinically reviewed by Jessica Boggs, MSN, APRN, FNP-C, ENP-C, founder of Navara Health. Medical oversight by Simal Patel, MD.
Last reviewed November 16, 2026. This page is general information, not medical advice, and does not create a provider relationship.
Sources
- Writing Group for the PEPI Trial. Effects of Hormone Therapy on Endometrial Histology. JAMA, 1996.
- Kim D et al. Hormone Therapy and Risk of Endometrial Hyperplasia or Cancer. Cochrane Database of Systematic Reviews, 2025.
- Steiner AZ et al. Unopposed Estradiol Therapy in Postmenopausal Women. Obstetrics and Gynecology, 2007.
- Brinton LA, Felix AS. Menopausal Hormone Therapy and Risk of Endometrial Cancer. 2014.
- Constantine GD et al. Endometrial Safety of Low-Dose Vaginal Estrogens. Menopause, 2019.
- AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause, 2025.
- Department of Veterans Affairs and Department of Defense. Clinical Practice Guideline for Menopause, 2026.
